Background:  This is a randomized, superiority, double blind, placebo-controlled, multicenter study comparing evolocumab 420mg  SC vs. placebo administered in the acute phase of ACS. The aim is to evaluate the effectiveness of the PCSK9 inhibitor  evolocumab as compared with placebo for reduction of LDL-C levels within 8 weeks in patients receiving  guideline-recommended high-intensity statin treatment (atorvastatin 40mg QD).   Sponsor: Inselspital Bern, Prof. Dr. Stephan Windecker  Trial Registration No: NCT03287609 ( Link  Trial Status: recruiting  Enrolling Centers:  Bern, Basel, Fribourg, Genf, Lausanne, Lugano, Zürich  Core Study Team: 
© Christian Mueller, 2012 - 2020 │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: Mai 2020
Home News Team Studies Publications Events Cooperations Contact Ina-Maria Ferel, Ph.D.